TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07269145: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 86 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,005,768

Rescue Site Savings

+$4,618,152

Unlock Full NCT07269145 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07269145 Rescue Dossier →